2025-08-26 21:50:09,705 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Processing and chunking clinical trials data...
2025-08-26 21:50:09,953 - clinical_trials_agent1.clinical_trials_chunker - INFO - Created 1060 chunks from 190 studies
2025-08-26 21:50:09,953 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Limited chunks to 200 for processing efficiency
2025-08-26 21:50:09,953 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Created 200 chunks from clinical trials data
2025-08-26 21:50:09,953 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Vectorizing 200 chunks...
2025-08-26 21:50:14,213 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/embeddings "HTTP/1.1 200 OK"
2025-08-26 21:50:18,559 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/embeddings "HTTP/1.1 200 OK"
2025-08-26 21:50:23,317 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/embeddings "HTTP/1.1 200 OK"
2025-08-26 21:50:27,106 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/embeddings "HTTP/1.1 200 OK"
2025-08-26 21:50:28,408 - clinical_trials_agent1.clinical_trials_vectorizer - INFO - Successfully embedded 200 texts
2025-08-26 21:50:28,424 - clinical_trials_agent1.clinical_trials_vectorizer - INFO - Successfully embedded 200 clinical trial chunks
2025-08-26 21:50:28,424 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Successfully vectorized 200 chunks
2025-08-26 21:50:28,424 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Retrieving relevant context for query: '**Brief Title**: Comparative Study on Costs and Outcomes of Transradial and Transfemoral Percutaneous Coronary Intervention

**Detailed Summary**: This study aimed to evaluate the costs and outcomes of transradial percutaneous coronary intervention (TRI) and transfemoral percutaneous coronary intervention (TFI) from a hospital perspective. The study was conducted at five U.S. centers and involved 7,121 PCI procedures performed from January 1, 2010, to March 31, 2011. The primary outcome was the cost of PCI hospitalization, while secondary outcomes included bleeding, in-hospital mortality, and length of stay. The study found that TRI was associated with shorter lengths of stay, lower bleeding events, and a total cost savings of $830 per patient compared to TFI. The cost savings were particularly significant among patients at higher predicted risk of bleeding.

**Study Design**: Retrospective Observational Study

**Patient Population**: The study involved 7,121 patients who underwent PCI procedures at five U.S. centers from January 1, 2010, to March 31, 2011. Of these, 1,219 (17%) patients underwent TRI.

**Intervention(s)**: The primary intervention being tested was transradial percutaneous coronary intervention (TRI).

**Comparator(s)**: The TRI was compared against transfemoral percutaneous coronary intervention (TFI).

**Primary Endpoint(s)**: The primary outcome was the cost of PCI hospitalization, defined as cost on the day of PCI through hospital discharge.

**Secondary Endpoint(s)**: Secondary outcomes of interest were bleeding, in-hospital mortality, and length of stay.

**Key Findings**: The study found that TRI was associated with shorter lengths of stay (2.5 vs. 3.0 days; p < 0.001) and lower bleeding events (1.1% vs. 2.4%, adjusted odds ratio [OR]: 0.52, 95% confidence interval [CI]: 0.34 to 0.79; p ¼ 0.002). TRI was associated with a total cost savings of $830 (95% CI: $296 to $1,364; p < 0.001), of which $130 (95% CI: –$99 to $361; p ¼ 0.112) were procedural savings and $705 (95% CI: $212 to $1,238; p < 0.001) were post-procedural savings. There was an associated graded increase in savings among patients at higher predicted risk of bleeding: low risk: $642 (95% CI: $43 to $1,236; p ¼ 0.035); moderate risk: $706 (95% CI: $104 to $1,308; p ¼ 0.029); and high risk: $1,621 (95% CI: $271 to $2,971, p ¼ 0.039).'
2025-08-26 21:50:29,995 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/embeddings "HTTP/1.1 200 OK"
2025-08-26 21:50:30,020 - clinical_trials_agent1.clinical_trials_vectorizer - INFO - Found 10 most similar chunks out of 200 total chunks
2025-08-26 21:50:30,023 - clinical_trials_agent1.clinical_trials_context_extractor - INFO - Filtered 10 chunks to 10 chunks above similarity threshold 0.3
2025-08-26 21:50:30,023 - clinical_trials_agent1.clinical_trials_context_extractor - INFO - Applied chunk type prioritization based on query content
2025-08-26 21:50:30,024 - clinical_trials_agent1.clinical_trials_context_extractor - INFO - Formatted context from 10 chunks, total length: 14197 characters
2025-08-26 21:50:30,024 - clinical_trials_agent1.clinical_trials_context_extractor - INFO - Extracted metadata for 7 unique studies
2025-08-26 21:50:30,024 - clinical_trials_agent1.clinical_trials_rag_pipeline - INFO - Retrieved context from 10 relevant chunks
Matched NCT ID: NCT01398254
Matched NCT ID: NCT02831166
Matched NCT ID: NCT01803841
Matched NCT ID: NCT01794325
Matched NCT ID: NCT01364532
Matched NCT ID: NCT04801901
Matched NCT ID: NCT01406236
{'NCT01398254': {'protocolSection': {'identificationModule': {'nctId': 'NCT01398254', 'orgStudyIdInfo': {'id': 'MRL-SS'}, 'secondaryIdInfos': [{'id': '2011311-01H'}], 'organization': {'fullName': 'Ottawa Heart Institute Research Corporation', 'class': 'OTHER'}, 'briefTitle': 'Femoral Versus Radial Access for Primary PCI', 'officialTitle': 'The Safety and Efficacy of Femoral Access Versus Radial for Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (SAFARI-STEMI Trial)', 'acronym': 'SAFARI-STEMI'}, 'statusModule': {'statusVerifiedDate': '2019-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-07'}, 'primaryCompletionDateStruct': {'date': '2018-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-01-16', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-07-13', 'studyFirstSubmitQcDate': '2011-07-18', 'studyFirstPostDateStruct': {'date': '2011-07-20', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-01-25', 'lastUpdatePostDateStruct': {'date': '2019-01-29', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Michel Le May', 'investigatorTitle': 'Director of Regional ACS Programs', 'investigatorAffiliation': 'Ottawa Heart Institute Research Corporation'}, 'leadSponsor': {'name': 'Ottawa Heart Institute Research Corporation', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Primary percutaneous coronary intervention (PPCI) has become the dominant strategy for the treatment of ST-elevation myocardial infarction (STEMI), as studies have shown that PPCI is superior to fibrinolytic therapy. Recent evidence suggests that transradial access (TRA) is superior to transfemoral (TFA) for patients undergoing PPCI. Two large trials report a mortality benefit favouring TRA. The results of these two trials could significantly impact practice guidelines and lead to a recommendation that the approach of choice for primary PCI be radial rather than femoral. This would have significant implications for both PCI centers and interventionalists associated with a large impact on practice and education. Yet, many centers and interventionalists in Canada and in the USA prefer TFA and currently feel pressured in making the change to TRA. With that said, these trials did not include new pharmacotherapy and new technology that would likely have closed or eliminated the gap between TFA and TRA by improving the safety and efficacy of these two approaches. Furthermore, these trials were not powered to conclusively show a mortality benefit. The authors of the two large trials emphasized the need for further trials to confirm the benefits of TRA.\n\nThe SAFARI-STEMI trial aims to compare TFA with TRA in patients undergoing primary percutaneous intervention (PPCI). The primary outcome will be defined as all cause mortality measured at 30 days. The trial will also evaluate: 1) bleeding events and 2) the composite of death, reinfarction, or stroke defined as major adverse clinical events (MACE). The trial will include the use of antithrombotic therapy with monotherapy, with either bivalirudin or unfractionated heparin; the use of glycoprotein inhibitors IIb/IIIa inhibitors will be avoided. The study will encourage liberal use of vascular closing devices. The trial will also compare delays to reperfusion between the two strategies. Finally, a cost analysis is proposed.\n\nIn view of recent publications, there is now a need for a large randomized trial using contemporary adjunct therapies to assess the safety and efficacy of the TRA vs. the TFA in PPCI. The proposed trial aims to conclusively show whether there is a survival benefit associated with the TRA approach.'}, 'conditionsModule': {'conditions': ['Myocardial Infarction', 'STEMI'], 'keywords': ['ST-Elevation Myocardial Infarction', 'Mortality']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 2292, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'TRA', 'type': 'OTHER', 'description': 'Transradial Access', 'interventionNames': ['Procedure: Primary Percutaneous Coronary Intervention (PPCI)']}, {'label': 'TFA', 'type': 'OTHER', 'description': 'Transfemoral Access', 'interventionNames': ['Procedure: Primary Percutaneous Coronary Intervention (PPCI)']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Primary Percutaneous Coronary Intervention (PPCI)', 'description': 'Participants will be randomly assigned an access site, radial or femoral, for PPCI.', 'armGroupLabels': ['TFA', 'TRA']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'All-cause mortality', 'description': 'The primary outcomes will be all-cause mortality measured at 30 days.', 'timeFrame': '30 days'}], 'secondaryOutcomes': [{'measure': 'Death, reinfarction, or stroke', 'timeFrame': '30 days and 6 months'}, {'measure': 'All-cause mortality', 'timeFrame': '6 months'}, {'measure': 'Reinfarction', 'timeFrame': '30 days and 6 months'}, {'measure': 'Stroke', 'timeFrame': '30 days and 6 months'}, {'measure': 'Stent thrombosis', 'timeFrame': '30 days and 6 months'}, {'measure': 'Bleeding', 'timeFrame': '30 days'}, {'measure': 'Number of blood transfusions', 'timeFrame': '30 days'}, {'measure': 'Cardiogenic shock', 'timeFrame': '30 days'}, {'measure': 'Critical time intervals (including door-to-balloon time)', 'timeFrame': 'Index hospitalization'}, {'measure': 'Fluoroscopy time and radiation exposure', 'timeFrame': 'Index Catheterization'}, {'measure': 'Length of Hospital Stay', 'timeFrame': 'Index hospitalization'}, {'measure': 'Resource utilization', 'timeFrame': '30 days'}]}, 'eligibilityModule': {'eligibilityCriteria': "Inclusion Criteria:\n\n1. Ischemic chest discomfort of greater or equal to 30 minutes duration,\n2. Onset of chest pain of greater or equal to 12 hrs prior to entry into the study,\n3. ST segment elevation of \\> 1 mm (0.1 mV) in two or more contiguous electrocardiographic leads (on a standard 12 lead ECG) or left bundle branch block not known to be old\n\nExclusion Criteria:\n\n1. Age \\< 18 yrs\n2. Active bleeding\n3. Inadequate vascular access from the femoral arteries (i.e. severe peripheral vascular artery disease precluding right or left femoral approach)\n4. Abnormal Allen's test precluding either right or left radial approach\n5. PCI within the last 30 days\n6. Fibrinolytic agents within the last 7 days\n7. Warfarin, dabigatran or other oral anticoagulant within the last 7 days\n8. Known coagulation disorder (i.e. INR \\>2.0, platelets \\<100,000 / mm3)\n9. Allergy to aspirin\n10. Participation in a study with another investigational device or drug \\< four weeks\n11. Known severe renal impairment (creatinine \\>200 umol/L)\\*\n12. Known severe contrast (dye) allergy\n13. Prior coronary artery bypass surgery\n14. Inability to provide informed consent\n\n    * Bivalirudin is contraindicated in renal failure.", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Michel R Le May, MD', 'affiliation': 'Ottawa Heart Institute Research Corporation', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'St. Boniface Hospital', 'city': 'Winnipeg', 'state': 'Manitoba', 'zip': 'R2H 2A6', 'country': 'Canada', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'facility': 'Saint John Regional Hospital', 'city': 'Saint John', 'state': 'New Brunswick', 'zip': 'E2L 4L2', 'country': 'Canada', 'geoPoint': {'lat': 45.2727, 'lon': -66.06769}}, {'facility': 'Queen Elizabeth II Health Sciences Center', 'city': 'Halifax', 'state': 'Nova Scotia', 'zip': 'B3H 4G4', 'country': 'Canada', 'geoPoint': {'lat': 44.64533, 'lon': -63.57239}}, {'facility': 'University of Ottawa Heart Institute', 'city': 'Ottawa', 'state': 'Ontario', 'zip': 'K1Y 4W7', 'country': 'Canada', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'facility': 'Thunder Bay Regional Health Sciences Center', 'city': 'Thunder Bay', 'state': 'Ontario', 'zip': 'P7B 6V4', 'country': 'Canada', 'geoPoint': {'lat': 48.38202, 'lon': -89.25018}}]}, 'referencesModule': {'references': [{'pmid': '33422518', 'type': 'DERIVED', 'citation': 'Marbach JA, Wells G, Santo PD, So D, Chong AY, Russo J, Labinaz M, Dick A, Froeschl M, Glover C, Hibbert B, Marquis JF, MacDougall A, Kass M, Paddock V, Quraishi AUR, Chandrasekhar J, Ghosh N, Bernick J, Le May M. Acute kidney injury after radial or femoral artery access in ST-segment elevation myocardial infarction: AKI-SAFARI. Am Heart J. 2021 Apr;234:12-22. doi: 10.1016/j.ahj.2020.12.019. Epub 2021 Jan 7.'}, {'pmid': '31895439', 'type': 'DERIVED', 'citation': 'Le May M, Wells G, So D, Chong AY, Dick A, Froeschl M, Glover C, Hibbert B, Marquis JF, Blondeau M, Osborne C, MacDougall A, Kass M, Paddock V, Quraishi A, Labinaz M. Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial. JAMA Cardiol. 2020 Feb 1;5(2):126-134. doi: 10.1001/jamacardio.2019.4852.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009203', 'term': 'Myocardial Infarction'}, {'id': 'D000072657', 'term': 'ST Elevation Myocardial Infarction'}, {'id': 'D007238', 'term': 'Infarction'}], 'ancestors': [{'id': 'D007511', 'term': 'Ischemia'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D009336', 'term': 'Necrosis'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M10282', 'name': 'Infarction', 'asFound': 'Infarction', 'relevance': 'HIGH'}, {'id': 'M12155', 'name': 'Myocardial Infarction', 'asFound': 'Myocardial Infarction', 'relevance': 'HIGH'}, {'id': 'M1072', 'name': 'ST Elevation Myocardial Infarction', 'asFound': 'ST Elevation Myocardial Infarction', 'relevance': 'HIGH'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M12284', 'name': 'Necrosis', 'relevance': 'LOW'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'relevance': 'LOW'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}}, 'hasResults': False}, 'NCT02831166': {'protocolSection': {'identificationModule': {'nctId': 'NCT02831166', 'orgStudyIdInfo': {'id': '50120915.1.0000.5413'}, 'organization': {'fullName': 'Irmandade Santa Casa Misericórdia Marília', 'class': 'OTHER'}, 'briefTitle': 'Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention', 'officialTitle': 'A Randomized Comparison Between Transfemoral Approach With Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention', 'acronym': 'ARISE-2'}, 'statusModule': {'statusVerifiedDate': '2020-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2019-11', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2016-07-02', 'studyFirstSubmitQcDate': '2016-07-08', 'studyFirstPostDateStruct': {'date': '2016-07-13', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-02-10', 'lastUpdatePostDateStruct': {'date': '2020-02-11', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Pedro Beraldo de Andrade', 'investigatorTitle': 'MD, phD', 'investigatorAffiliation': 'Irmandade Santa Casa Misericórdia Marília'}, 'leadSponsor': {'name': 'Irmandade Santa Casa Misericórdia Marília', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Primary percutaneous coronary intervention represents the gold standard for the treatment of ST-segment-elevation acute myocardial infarction. However, periprocedural bleedings are associated with an increased risk of mortality, re-infarction, and stroke. Although the prognostic value of access site related bleeding complications is still debated, transradial approach is associated with better short-term outcomes and reduced hospital stay as compared to transfemoral approach. The investigators aimed to compare transradial approach with transfemoral approach with systematic achievement of hemostasis by the implantation of a vascular closure device in a national multicentre randomized clinical trial.'}, 'conditionsModule': {'conditions': ['Myocardial Infarction', 'Complications; Device, Vascular', 'Injury of Radial Artery', 'Injury; Blood Vessel, Femoral, Artery'], 'keywords': ['Vascular closure devices', 'Transradial approach', 'Transfemoral approach']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 250, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Transradial approach', 'type': 'ACTIVE_COMPARATOR', 'description': 'Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=125).', 'interventionNames': ['Procedure: Transradial primary percutaneous coronary intervention']}, {'label': 'Transfemoral approach', 'type': 'ACTIVE_COMPARATOR', 'description': 'Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=125).', 'interventionNames': ['Procedure: Transfemoral primary percutaneous coronary intervention']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Transradial primary percutaneous coronary intervention', 'description': 'Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.', 'armGroupLabels': ['Transradial approach']}, {'type': 'PROCEDURE', 'name': 'Transfemoral primary percutaneous coronary intervention', 'description': 'Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.', 'armGroupLabels': ['Transfemoral approach']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Major vascular access site complications', 'description': 'Major vascular complications related to arterial access site will be evaluated during hospitalization by physical examination and duplex ultrassonography and include major bleeding, retroperitoneal hemorrhage, compartment syndrome, pseudoaneurysm, arteriovenous fistula, limb ischemia or need for vascular surgery repair.', 'timeFrame': '48 hours post-procedure'}], 'secondaryOutcomes': [{'measure': 'Device success', 'description': 'The success of the device is defined as the attainment of adequate hemostasis at the end of the procedure, without the need to apply other compression methods.', 'timeFrame': '48 hours post-procedure'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset;\n* Intention to perform primary percutaneous coronary intervention;\n* Signed informed consent;\n* Patient eligible for transradial and transfemoral primary percutaneous coronary intervention, being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process.\n\nExclusion Criteria:\n\n* Less than 18 years of age;\n* Pregnancy;\n* Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists;\n* Hypersensitivity to antiplatelet and/or anticoagulant drugs;\n* Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance \\< 30 mL/min, platelets count \\< 100.000 mm3);\n* Uncontrolled systemic hypertension;\n* Cardiogenic shock;\n* Previous myocardial revascularization surgery with ≥ 1 internal mammary or radial artery graft;\n* Documented chronic peripheral arterial disease preventing the use of the femoral technique;\n* Severe concomitant disease with life expectancy below 12 months;\n* Participation in drug or devices investigative clinical trials in the last 30 days;\n* Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Pedro B Andrade, phD', 'affiliation': 'Irmandade SCMM', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Pedro Beraldo de Andrade', 'city': 'Marília', 'state': 'São Paulo', 'zip': '17515900', 'country': 'Brazil', 'geoPoint': {'lat': -22.21389, 'lon': -49.94583}}]}, 'referencesModule': {'references': [{'pmid': '24345099', 'type': 'BACKGROUND', 'citation': 'de Andrade PB, E Mattos LA, Tebet MA, Rinaldi FS, Esteves VC, Nogueira EF, Franca JI, de Andrade MV, Barbosa RA, Labrunie A, Abizaid AA, Sousa AG. Design and rationale of the AngioSeal versus the Radial approach In acute coronary SyndromE (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients. Trials. 2013 Dec 18;14:435. doi: 10.1186/1745-6215-14-435.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009203', 'term': 'Myocardial Infarction'}, {'id': 'D057772', 'term': 'Vascular System Injuries'}, {'id': 'D007238', 'term': 'Infarction'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}], 'ancestors': [{'id': 'D007511', 'term': 'Ischemia'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D009336', 'term': 'Necrosis'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M10282', 'name': 'Infarction', 'asFound': 'Infarction', 'relevance': 'HIGH'}, {'id': 'M12155', 'name': 'Myocardial Infarction', 'asFound': 'Myocardial Infarction', 'relevance': 'HIGH'}, {'id': 'M28858', 'name': 'Vascular System Injuries', 'asFound': 'Injury; Blood Vessel', 'relevance': 'HIGH'}, {'id': 'M17685', 'name': 'Wounds and Injuries', 'asFound': 'Injury', 'relevance': 'HIGH'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M12284', 'name': 'Necrosis', 'relevance': 'LOW'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'relevance': 'LOW'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M9576', 'name': 'Hemostatics', 'relevance': 'LOW'}, {'id': 'M4854', 'name': 'Benzocaine', 'relevance': 'LOW'}, {'id': 'T433', 'name': 'Tannic Acid', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Coag', 'name': 'Coagulants'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}, {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}}, 'hasResults': False}, 'NCT01803841': {'protocolSection': {'identificationModule': {'nctId': 'NCT01803841', 'orgStudyIdInfo': {'id': 'KOTRI'}, 'organization': {'fullName': 'Yonsei University', 'class': 'OTHER'}, 'briefTitle': 'Korea Transradial Coronary Intervention Prospective Registry (KOTRI)', 'officialTitle': 'Korea Transradial Coronary Intervention Prospective Registry (KOTRI)', 'acronym': 'KOTRI'}, 'statusModule': {'statusVerifiedDate': '2016-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-02'}, 'primaryCompletionDateStruct': {'date': '2015-04', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-06', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-02-25', 'studyFirstSubmitQcDate': '2013-03-01', 'studyFirstPostDateStruct': {'date': '2013-03-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-11-14', 'lastUpdatePostDateStruct': {'date': '2016-11-15', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Yoon Junghan', 'investigatorTitle': 'Professor of Cardiology, Department of Internal Medicine', 'investigatorAffiliation': 'Yonsei University'}, 'leadSponsor': {'name': 'Yonsei University', 'class': 'OTHER'}, 'collaborators': [{'name': 'The Korean Society of Cardiology', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The aim of this registry is to analyze several factors affecting the procedural success and clinical outcomes at 1 year of follow-up according to the approach site.', 'detailedDescription': 'This registry is a multi-center prospective registry for patients undergoing coronary angiography or percutaneous coronary intervention either transradial or transfemoral approach from 22 centers in South Korea. The aim of this registry is to analyze several factors affecting the procedural success and clinical outcomes at 1 year of follow-up according to the approach site.'}, 'conditionsModule': {'conditions': ['Coronary Artery Disease'], 'keywords': ['Coronary artery disease']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 7300, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Transradial access', 'type': 'ACTIVE_COMPARATOR', 'description': 'Coronary angiography and intervention via radial artery approach', 'interventionNames': ['Procedure: Transradial coronary angiography and intervention']}, {'label': 'Transfemoral access', 'type': 'ACTIVE_COMPARATOR', 'description': 'Coronary angiography and intervention via femoral artery approach', 'interventionNames': ['Procedure: Transfemoral coronary angiography and intervention']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Transradial coronary angiography and intervention', 'armGroupLabels': ['Transradial access']}, {'type': 'PROCEDURE', 'name': 'Transfemoral coronary angiography and intervention', 'armGroupLabels': ['Transfemoral access']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Patient-oriented composite outcome', 'description': 'The composite of any death, non-fatal myocardial infarction, and any revascularization', 'timeFrame': '1 year'}], 'secondaryOutcomes': [{'measure': 'Access failure', 'description': 'Conversion rate of access site', 'timeFrame': 'Day 0 (end of procedure)'}, {'measure': 'Success of percutaneous coronary intervention', 'description': 'Combination of angiographic success and procedural success\n\n1. Angiographic success; thrombolysis in myocardial infarction (TIMI) flow grad 3 and \\<30% residual diameter stenosis\n2. Procedural success; Angiographic success without major procedural or in-hospital complications such as death, Q-wave myocardial infarction, or emergency bypass surgery', 'timeFrame': 'Day 3 (day of discharge)'}, {'measure': 'Procedure time', 'description': 'Procedure time according to the access site', 'timeFrame': 'Day 0 (end of procedure)'}, {'measure': 'Fluoroscopic time', 'description': 'Fluoroscopic time according to the access site', 'timeFrame': 'Day 0 (end of procedure)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* All consecutive hospitalized patients undergoing coronary angiography or percutaneous coronary intervention\n\nExclusion Criteria:\n\n* No exclusion criteria', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '19 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Wonju Severance Christian Hospital', 'city': 'Wonju', 'state': 'Gangwon', 'zip': '220-701', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.35139, 'lon': 127.94528}}]}, 'referencesModule': {'references': [{'pmid': '27026640', 'type': 'BACKGROUND', 'citation': 'Choe JC, Cha KS, Choi JH, Kim BW, Park JS, Lee HW, Oh JH, Choi JH, Lee HC, Hong TJ, Youn YJ, Lee SH, Cho BR, Kim DI, Han KR, Jeong MH, Yoon J; Korea Transradial Coronary Intervention (KOTRI) Prospective Registry Investigators. Comparison of Frequency of Bleeding and Major Adverse Cardiac Events After Transradial Versus Transfemoral Intervention in the Recent Antiplatelet Era. Am J Cardiol. 2016 May 15;117(10):1588-1595. doi: 10.1016/j.amjcard.2016.02.033. Epub 2016 Mar 2.'}, {'pmid': '27018932', 'type': 'BACKGROUND', 'citation': 'Lee SH, Jeong MH, Han KR, Sim DS, Yoon J, Youn YJ, Cho BR, Cha KS, Hyon MS, Rha SW, Kim BO, Shin WY, Park KS, Cheong SS; Korean Transradial Coronary Intervention Registry Investigators. Comparison of Transradial and Transfemoral Approaches for Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome and Anemia. Am J Cardiol. 2016 May 15;117(10):1582-1587. doi: 10.1016/j.amjcard.2016.02.030. Epub 2016 Mar 2.'}, {'pmid': '26617647', 'type': 'RESULT', 'citation': 'Youn YJ, Lee JW, Ahn SG, Lee SH, Yoon J, Cho BR, Cheong SS, Kim HY, Lee JH, Bae JH, Lee JB, Suh J, Park KS, Han KR, Jeong MH, Rha SW, Her SH, Cho YH, Kim SW. Current Practice of Transradial Coronary Angiography and Intervention: Results from the Korean Transradial Intervention Prospective Registry. Korean Circ J. 2015 Nov;45(6):457-68. doi: 10.4070/kcj.2015.45.6.457. Epub 2015 Nov 25.'}], 'seeAlsoLinks': [{'label': 'TRI retrospective registry electronic case report form (eCRF)', 'url': 'http://tricrf.medsoft.co.kr'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003324', 'term': 'Coronary Artery Disease'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D003327', 'term': 'Coronary Disease'}], 'ancestors': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M6546', 'name': 'Coronary Artery Disease', 'asFound': 'Coronary Artery Disease', 'relevance': 'HIGH'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'asFound': 'Coronary Artery Disease', 'relevance': 'HIGH'}, {'id': 'M6549', 'name': 'Coronary Disease', 'asFound': 'Coronary Artery Disease', 'relevance': 'HIGH'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M4469', 'name': 'Arteriosclerosis', 'relevance': 'LOW'}, {'id': 'M4465', 'name': 'Arterial Occlusive Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, 'NCT01794325': {'protocolSection': {'identificationModule': {'nctId': 'NCT01794325', 'orgStudyIdInfo': {'id': 'UP 4786/12'}, 'organization': {'fullName': 'Instituto de Cardiologia do Rio Grande do Sul', 'class': 'OTHER'}, 'briefTitle': 'Transradial and Transfemoral Coronary Angiography by EXPERienced operaTors', 'officialTitle': 'Transradial and Transfemoral Approach by EXPERienced Operators in Daily rouTine (EXPERT): a Randomized, Non-inferiority Trial', 'acronym': 'EXPERT'}, 'statusModule': {'statusVerifiedDate': '2014-09', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-02'}, 'primaryCompletionDateStruct': {'date': '2014-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2014-03', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-02-15', 'studyFirstSubmitQcDate': '2013-02-15', 'studyFirstPostDateStruct': {'date': '2013-02-18', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-09-16', 'lastUpdatePostDateStruct': {'date': '2014-09-17', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Instituto de Cardiologia do Rio Grande do Sul', 'class': 'OTHER'}, 'collaborators': [{'name': 'Hospital Ernesto Dornelles', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': "Transradial approach (TRA) reduces vascular complications and access related-bleeding compared to transfemoral approach (TFA). However, this technique has been related to higher radiation exposure during coronary angiography and percutaneous coronary intervention. Previous studies have shown that TRA demands a long learning curve, and procedure success rate increases with operator's experience. Our hypothesis is that the higher radiation exposure during TRA is not a technique issue, but due to operator's expertise.\n\nThe aim of this study is to evaluate whether experienced operators with either TRA or TFA can perform diagnostic coronary angiography with similar radiation exposure."}, 'conditionsModule': {'conditions': ['Exposure to Ionizing Radiation', 'Coronary Heart Disease', 'Vascular Access Complication'], 'keywords': ['Occupational radiation exposure', 'Transradial approach', 'Transfemoral approach']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Trans-radial access', 'type': 'ACTIVE_COMPARATOR', 'description': 'Coronary angiography performed through trans-radial access', 'interventionNames': ['Other: Trans-radial']}, {'label': 'Trans-femoral access', 'type': 'ACTIVE_COMPARATOR', 'description': 'Coronary angiography performed through trans-femoral access', 'interventionNames': ['Other: Trans-femoral']}], 'interventions': [{'type': 'OTHER', 'name': 'Trans-radial', 'description': 'Coronary angiography performed through trans-radial access', 'armGroupLabels': ['Trans-radial access']}, {'type': 'OTHER', 'name': 'Trans-femoral', 'description': 'Coronary angiography performed through trans-femoral access', 'armGroupLabels': ['Trans-femoral access']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Patient radiation exposure (mGy)', 'description': 'Patient radiation exposure (mGy)', 'timeFrame': 'during coronary angiography'}], 'secondaryOutcomes': [{'measure': 'Physician radiation exposure (in uSv)', 'description': 'Physician radiation exposure (in uSv)', 'timeFrame': 'during coronary angiography'}], 'otherOutcomes': [{'measure': 'Major adverse cardiac events', 'description': 'Major adverse cardiac events (death, stroke and vascular complications)', 'timeFrame': '30 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Indication for a elective coronary angiography\n* Eligible for either transfemoral or transradial approach\n* Accept to sign the written consent form (WCF)\n\nExclusion Criteria:\n\n* Refusal to sign the WCF\n* End stage renal failure\n* Urgency/Emergency procedure\n* Contraindication to perform both coronary and left ventricle angiogram\n* Necessity of another vascular angiogram during coronary angiography', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '21 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Cristiano O Cardoso, MD, MSc', 'affiliation': 'Instituto de Cardiologia do Rio Grande do Sul', 'role': 'STUDY_CHAIR'}, {'name': 'Luis M Yordi, MD', 'affiliation': 'Hospital Ernesto Dornelles', 'role': 'STUDY_DIRECTOR'}, {'name': 'Claudio V Moraes, MD', 'affiliation': 'Insituto de Cardiologia do Rio Grande do Sul', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Instituto de Cardiologia do Rio Grande do Sul', 'city': 'Porto Alegre', 'state': 'RS', 'zip': '90520-000', 'country': 'Brazil', 'geoPoint': {'lat': -30.03306, 'lon': -51.23}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D003327', 'term': 'Coronary Disease'}, {'id': 'D003324', 'term': 'Coronary Artery Disease'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}], 'ancestors': [{'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}], 'browseLeaves': [{'id': 'M6546', 'name': 'Coronary Artery Disease', 'asFound': 'Coronary Heart Disease', 'relevance': 'HIGH'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'asFound': 'Coronary Heart Disease', 'relevance': 'HIGH'}, {'id': 'M6549', 'name': 'Coronary Disease', 'asFound': 'Coronary Heart Disease', 'relevance': 'HIGH'}, {'id': 'M9419', 'name': 'Heart Diseases', 'asFound': 'Heart Disease', 'relevance': 'HIGH'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M4469', 'name': 'Arteriosclerosis', 'relevance': 'LOW'}, {'id': 'M4465', 'name': 'Arterial Occlusive Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, 'NCT01364532': {'protocolSection': {'identificationModule': {'nctId': 'NCT01364532', 'orgStudyIdInfo': {'id': 'PATRASCARDIOLOGY-5'}, 'organization': {'fullName': 'University of Patras', 'class': 'OTHER'}, 'briefTitle': 'Transradial Versus Transulnar Artery Approach for Coronary Interventions', 'officialTitle': 'A Randomized Study of Transradial Versus Transulnar Artery Approach for Coronary Interventions', 'acronym': 'AURA'}, 'statusModule': {'statusVerifiedDate': '2011-04', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-04'}, 'primaryCompletionDateStruct': {'date': '2011-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2011-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2011-05-27', 'studyFirstSubmitQcDate': '2011-05-31', 'studyFirstPostDateStruct': {'date': '2011-06-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2011-05-31', 'lastUpdatePostDateStruct': {'date': '2011-06-02', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'George Hahalis', 'oldOrganization': 'Patras University Hospital'}, 'leadSponsor': {'name': 'University of Patras', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The transradial route is increasingly used as an access site in percutaneous coronary interventions, as it is considered equivalent to transfemoral approach in terms of efficacy but with a decreased vascular complication risk. Information concerning the efficacy and safety of transulnar approach is sparse. This is a prospective, randomized, investigator-initiated study to compare transradial versus transulnar approach as a default strategy for coronary angiography, ad-hoc or elective percutaneous coronary intervention (PCI). Consecutive eligible patients with an indication for coronary angiography, will be randomized after written informed consent in a 1:1 ratio to either transradial or transulnar access. Assessment of angiographic and procedural characteristics(including amount of contrast medium, arterial access, fluoroscopy and procedural time), as well as any vascular or other peri-procedural complications of the cases enrolled, will be performed. After hospital discharge, all patients will return at Day 60 ±5 days for Doppler ultrasound assessment of the forearm vessels and documentation of major adverse cardiovascular events (defined as death, myocardial infarction, target vessel revascularization and stroke. Coronary angiography patients will be additionally randomized in a 1:1 ratio to either 2500 or 5000 IU of unfractioned heparin.'}, 'conditionsModule': {'conditions': ['Arterial Access in Percutaneous Coronary Angiography or Intervention'], 'keywords': ['transulnar arterial access', 'transradial arterial access', 'percutaneous coronary intervention']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 572, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Transulnar arterial access', 'type': 'EXPERIMENTAL', 'description': 'Transulnar arterial access for coronary angiography, ad-hoc or elective PCI', 'interventionNames': ['Procedure: Transulnar arterial access']}, {'label': 'Transradial arterial access', 'type': 'ACTIVE_COMPARATOR', 'description': 'Transradial arterial access for coronary angiography, ad-hoc or elective PCI', 'interventionNames': ['Procedure: Transradial arterial access']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Transulnar arterial access', 'description': 'Transulnar arterial access in coronary angiography, ad-hoc or elective PCI', 'armGroupLabels': ['Transulnar arterial access']}, {'type': 'PROCEDURE', 'name': 'Transradial arterial access', 'description': 'Transradial arterial access for coronary angiography,ad-hoc or elective PCI', 'armGroupLabels': ['Transradial arterial access']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Successful arterial access free from need for crossover and free from vascular or coronary ischemic complications (MACEs)within 60± days', 'description': 'MACEs are considered both vascular and coronary ischemic complications. Vascular complications include arterial occlusion, local arterial perforation, compartment syndrome, pseudoaneurysm, fistula formation, major bleeding, hematoma of at least 10cm length, or any vascular damage requiring prolonged hospitalization or intervention.\n\nCoronary ishcemic complications include cardiac death, non fatal myocardial infarction, urgent repeat revascularization and stroke.', 'timeFrame': 'The primary end point will be assessed within 60±5 days after randomization'}], 'secondaryOutcomes': [{'measure': 'Fluoroscopy time', 'description': 'Fluoroscopy time (in seconds) assessed within 1 minute after the end of coronary angiography or coronary intervention', 'timeFrame': 'Fluoroscopy time will be assessed within 1 minute after the end of coronary angiography or coronary intervention'}, {'measure': 'Amount of contrast medium', 'description': 'Volume of contrast medium (ml) will be assessed within 1 minute after the end of coronary angiography or coronary intervention', 'timeFrame': 'The amount of contrast medium will be assessed within 1 minute after the end of coronary angiography or coronary intervention'}, {'measure': 'Vascular complication defined as post-procedural occlusion, perforation, pseudo-aneurysm, fistula or hematoma formation', 'description': 'Vascular complication (defined as post-procedural occlusion, perforation, pseudo-aneurysm, fistula or hematoma formation of at least 10 cm length, compartment syndrome) will be assessed 6 hours after the end of coronary angiography or intervention', 'timeFrame': 'Vascular complication will be assessed 6 hours after the end of coronary angiography or intervention'}, {'measure': 'Procedural duration (defined as the sum of arterial access, coronary angiography and coronary intervention duration)', 'description': 'Procedural duration (defined as the sum of arterial access, coronary angiography and coronary intervention duration)will be assessed within 1 minute after the end of coronary angiography or coronary intervention', 'timeFrame': 'Procedural duration will be assessed within 1 minute after the end of coronary angiography or coronary intervention'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age\\>18 years\n* Plan for Coro- and ad hoc PCI, if necessary\n* Written informed consent\n\nExclusion Criteria:\n\n* Cardiogenic shock, haemodynamic instability, Killip class III\n* Chronic hemodialysis\n* Coronary artery bypass grafting (CABG) with either bilateral internal mammary artery (IMA) or bilateral radial artery use', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '19 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Patras University Hospital', 'status': 'RECRUITING', 'city': 'Patras', 'state': 'Rion', 'zip': '26500', 'country': 'Greece', 'contacts': [{'name': 'George Hahalis, MD', 'role': 'CONTACT', 'phone': '00306932751222', 'email': 'ghahalis@otenet.gr'}, {'name': 'George Hahalis, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.24444, 'lon': 21.73444}}]}, 'referencesModule': {'references': [{'pmid': '23735472', 'type': 'DERIVED', 'citation': 'Hahalis G, Tsigkas G, Xanthopoulou I, Deftereos S, Ziakas A, Raisakis K, Pappas C, Sourgounis A, Grapsas N, Davlouros P, Galati A, Plakomyti TE, Mylona P, Styliadis I, Pyrgakis V, Alexopoulos D. Transulnar compared with transradial artery approach as a default strategy for coronary procedures: a randomized trial. The Transulnar or Transradial Instead of Coronary Transfemoral Angiographies Study (the AURA of ARTEMIS Study). Circ Cardiovasc Interv. 2013 Jun;6(3):252-61. doi: 10.1161/CIRCINTERVENTIONS.112.000150. Epub 2013 Jun 4.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}}, 'hasResults': False}, 'NCT04801901': {'protocolSection': {'identificationModule': {'nctId': 'NCT04801901', 'orgStudyIdInfo': {'id': 'U20-04-4021'}, 'organization': {'fullName': 'Inova Health Care Services', 'class': 'OTHER'}, 'briefTitle': 'Distal Transradial Access for Percutaneous Coronary Intervention', 'officialTitle': 'PRESERVE Radial: A PRospEctive Randomized Clinical Study Comparing Radial ArtERy Intimal Hyperplasia Following Distal Vs. ForEarm TransRadial Arterial Access for Coronary Angiography'}, 'statusModule': {'statusVerifiedDate': '2022-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-10-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-07-29', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-07-29', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2021-01-07', 'studyFirstSubmitQcDate': '2021-03-13', 'studyFirstPostDateStruct': {'date': '2021-03-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-08-12', 'lastUpdatePostDateStruct': {'date': '2022-08-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Dr. Wayne B. Batchelor M.D.', 'investigatorTitle': 'Director of Interventional Cardiology, Inova Heart and Vascular Institute', 'investigatorAffiliation': 'Inova Health Care Services'}, 'leadSponsor': {'name': 'Inova Health Care Services', 'class': 'OTHER'}, 'collaborators': [{'name': 'Boston Scientific Corporation', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Prospective randomized non-blinded study to determine degree of vessel trauma and adverse remodeling of the proximal forearm radial artery following distal radial artery access (dTRA) for cardiac catheterization compared to standard forearm transradial access (fTRA).', 'detailedDescription': 'To determine degree of vessel trauma and adverse remodeling of the proximal forearm radial artery, using ultrahigh resolution (55 MHz) ultrasound, following distal radial artery access (dTRA) for cardiac catheterization compared to standard forearm transradial access (fTRA) at 90 days post-procedure. Secondary outcome measures will include metrics of procedural success at 24 hours, as well as functional assessment of pain and motor strength of the ipsilateral upper extremity at 90 days post-procedure.'}, 'conditionsModule': {'conditions': ['Transradial Access', 'Coronary Angiography', 'Radial Artery Intimal Medial Thickness', 'Distal Radial Artery Access (dTRA)']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective randomized non-blinded study evaluating whether distal radial artery access (dTRA) from the anatomic snuffbox is associated with less trauma and adverse remodeling to the forearm radial artery compared to standardard forearm radial access (fTRA).', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 64, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Distal transradial access (dTRA)', 'type': 'EXPERIMENTAL', 'description': 'Subjects randomized to the experimental arm will undergo left heart catheterization using distal transradial access (dTRA) to facilitate coronary angiography and/or percutaneous coronary intervention.', 'interventionNames': ['Procedure: dTRA']}, {'label': 'Forearm radial access (fTRA)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Cardiac catheterization to facilitate coronary angiography and/or percutaneous coronary intervention using the standard forearm radial artery which is the current standard of care in interventional cardiology.', 'interventionNames': ['Procedure: fTRA']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'dTRA', 'description': 'Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)', 'armGroupLabels': ['Distal transradial access (dTRA)']}, {'type': 'PROCEDURE', 'name': 'fTRA', 'description': 'Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.', 'armGroupLabels': ['Forearm radial access (fTRA)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Radial artery intimal medial thickness following dTRA and fTRA', 'description': 'Intimal medial thickness (mm) of the forearm radial artery followed dTRA and fTRA as assessed using ultrahigh resolution 55 MHz ultrasound probe at 90 days post cardiac catheterization.', 'timeFrame': '90 days post-cardiac catheterization.'}], 'secondaryOutcomes': [{'measure': 'Radial artery trauma followed dTRA and fTRA', 'description': 'Number of participants with limited access site intimal tears, dissections, thrombosis, occlusions and pseudoaneurysms of the radial artery as assessed using ultrahigh resolution 55 MHz ultrasound at the site of puncture at 90 days post cardiac catheterization', 'timeFrame': '90 days post-cardiac catheterization'}, {'measure': 'Functional assessment of the ipsilateral upper extremity following dTRA and fTRA', 'description': 'Pain and motor strength of the ipsilateral upper extremity using the Borg (0-none to 10-maximal) and Disabilities of the Arm, Shoulders and Hand (DASH) (0-no disability to 100-most severe disability) scales 90 days post-cardiac catheterization.', 'timeFrame': '90 days post-cardiac catheterization'}, {'measure': 'Number of cannulation attempts', 'description': 'Number of cannulation attempts prior to achieving successful vascular access', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Radial artery access time', 'description': 'Time (minutes) from initial attempt to successful access of the radial artery.', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Access site crossover', 'description': 'Number of patients with failure of radial artery cannulation requiring crossover to alternative radial artery access or transfemoral access', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Total procedural time', 'description': 'Total procedural time (minutes) from time of access to completion of the cardiac catheterization.', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Duration of hemostasis', 'description': 'Total duration of hemostasis (minutes) following completion of cardiac catheterization', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Incidence of hematomas', 'description': 'Number of patients with EASY Class III or greater hematomas', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Percutaneous Coronary Intervention Success', 'description': 'Achievement of Thrombolysis in Myocardial Infarction (TIMI) 3 flow following percutaneous coronary intervention', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Coronary dissection', 'description': 'Iatrogenic coronary dissection at the of cardiac catheterization', 'timeFrame': '24 hours post-cardiac catheterization'}, {'measure': 'Myocardial infarction requiring revascularization', 'description': 'Periprocedural myocardial infarction requiring urgent revascularization within 24 hours post-cardiac catheterization.', 'timeFrame': '24 hours post-cardiac catheterization'}]}, 'eligibilityModule': {'eligibilityCriteria': "Inclusion Criteria:\n\n1. Consecutive patients undergoing elective and non-emergent TR LHC and/or PCI at the INOVA Heart and Vascular Institute\n2. Able to provide informed consent.\n3. Patients willing to complete a 90day post PCI radial artery ultrasound.\n\nExclusion Criteria:\n\n1. Patients with previous cannulation of both the right and left forearm RA's for coronary angiography and/or PCI. In patients with prior cannulation of one RA, the contralateral arm may be used for this study.\n2. Patients who are not willing to undergo the necessary follow-up ultrasound examinations.\n3. ST elevation myocardial infarction or other emergent PCI\n4. Inability to provide informed consent", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Inova Fairfax Hospital', 'city': 'Falls Church', 'state': 'Virginia', 'zip': '22042', 'country': 'United States', 'geoPoint': {'lat': 38.88233, 'lon': -77.17109}}]}, 'referencesModule': {'references': [{'pmid': '2912567', 'type': 'BACKGROUND', 'citation': 'Campeau L. Percutaneous radial artery approach for coronary angiography. Cathet Cardiovasc Diagn. 1989 Jan;16(1):3-7. doi: 10.1002/ccd.1810160103.'}, {'pmid': '27372195', 'type': 'BACKGROUND', 'citation': 'Ferrante G, Rao SV, Juni P, Da Costa BR, Reimers B, Condorelli G, Anzuini A, Jolly SS, Bertrand OF, Krucoff MW, Windecker S, Valgimigli M. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2016 Jul 25;9(14):1419-34. doi: 10.1016/j.jcin.2016.04.014. Epub 2016 Jun 29.'}, {'pmid': '31473240', 'type': 'BACKGROUND', 'citation': 'Kopin D, Seth M, Sukul D, Dixon S, Aronow HD, Lee D, Tucciarone M, Pielsticker E, Gurm HS. Primary and Secondary Vascular Access Site Complications Associated With Percutaneous Coronary Intervention: Insights From the BMC2 Registry. JACC Cardiovasc Interv. 2019 Nov 25;12(22):2247-2256. doi: 10.1016/j.jcin.2019.05.051. Epub 2019 Aug 28.'}, {'pmid': '29102582', 'type': 'BACKGROUND', 'citation': 'Valle JA, Kaltenbach LA, Bradley SM, Yeh RW, Rao SV, Gurm HS, Armstrong EJ, Messenger JC, Waldo SW. Variation in the Adoption of Transradial Access for ST-Segment Elevation Myocardial Infarction: Insights From the NCDR CathPCI Registry. JACC Cardiovasc Interv. 2017 Nov 27;10(22):2242-2254. doi: 10.1016/j.jcin.2017.07.020. Epub 2017 Nov 1.'}, {'pmid': '30354598', 'type': 'BACKGROUND', 'citation': 'Mason PJ, Shah B, Tamis-Holland JE, Bittl JA, Cohen MG, Safirstein J, Drachman DE, Valle JA, Rhodes D, Gilchrist IC; American Heart Association Interventional Cardiovascular Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Council on Genomic and Precision Medicine. An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circ Cardiovasc Interv. 2018 Sep;11(9):e000035. doi: 10.1161/HCV.0000000000000035.'}, {'pmid': '26811162', 'type': 'BACKGROUND', 'citation': 'Rashid M, Kwok CS, Pancholy S, Chugh S, Kedev SA, Bernat I, Ratib K, Large A, Fraser D, Nolan J, Mamas MA. Radial Artery Occlusion After Transradial Interventions: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2016 Jan 25;5(1):e002686. doi: 10.1161/JAHA.115.002686.'}, {'pmid': '28506941', 'type': 'BACKGROUND', 'citation': 'Kiemeneij F. Left distal transradial access in the anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI). EuroIntervention. 2017 Sep 20;13(7):851-857. doi: 10.4244/EIJ-D-17-00079.'}, {'pmid': '20939038', 'type': 'BACKGROUND', 'citation': 'Babunashvili A, Dundua D. Recanalization and reuse of early occluded radial artery within 6 days after previous transradial diagnostic procedure. Catheter Cardiovasc Interv. 2011 Mar 1;77(4):530-6. doi: 10.1002/ccd.22846.'}, {'pmid': '30801939', 'type': 'BACKGROUND', 'citation': 'Aoi S, Htun WW, Freeo S, Lee S, Kyaw H, Alfaro V, Coppola J, Pancholy S, Kwan T. Distal transradial artery access in the anatomical snuffbox for coronary angiography as an alternative access site for faster hemostasis. Catheter Cardiovasc Interv. 2019 Nov 1;94(5):651-657. doi: 10.1002/ccd.28155. Epub 2019 Feb 24.'}, {'pmid': '30314833', 'type': 'BACKGROUND', 'citation': 'Koutouzis M, Kontopodis E, Tassopoulos A, Tsiafoutis I, Katsanou K, Rigatou A, Didagelos M, Andreou K, Lazaris E, Oikonomidis N, Maniotis C, Ziakas A. Distal Versus Traditional Radial Approach for Coronary Angiography. Cardiovasc Revasc Med. 2019 Aug;20(8):678-680. doi: 10.1016/j.carrev.2018.09.018. Epub 2018 Oct 2.'}, {'pmid': '32269880', 'type': 'BACKGROUND', 'citation': 'Nairoukh Z, Jahangir S, Adjepong D, Malik BH. Distal Radial Artery Access: The Future of Cardiovascular Intervention. Cureus. 2020 Mar 7;12(3):e7201. doi: 10.7759/cureus.7201.'}, {'pmid': '31880380', 'type': 'BACKGROUND', 'citation': 'Shroff AR, Gulati R, Drachman DE, Feldman DN, Gilchrist IC, Kaul P, Lata K, Pancholy SB, Panetta CJ, Seto AH, Speiser B, Steinberg DH, Vidovich MI, Woody WW, Rao SV. SCAI expert consensus statement update on best practices for transradial angiography and intervention. Catheter Cardiovasc Interv. 2020 Feb;95(2):245-252. doi: 10.1002/ccd.28672. Epub 2019 Dec 27.'}, {'pmid': '30108641', 'type': 'BACKGROUND', 'citation': 'Roghani-Dehkordi F, Hashemifard O, Sadeghi M, Mansouri R, Akbarzadeh M, Dehghani A, Akbari M. Distal accesses in the hand (two novel techniques) for percutaneous coronary angiography and intervention. ARYA Atheroscler. 2018 Mar;14(2):95-100. doi: 10.22122/arya.v14i2.1743.'}, {'pmid': '30336816', 'type': 'BACKGROUND', 'citation': 'Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045.'}, {'pmid': '29653651', 'type': 'BACKGROUND', 'citation': 'Batchelor W, Dahya V, McGee D, Katopodis J, Dixon W, Campbell J, Meredith A, Knap P, Parkin M, Noel T. Ultrahigh-resolution ultrasound characterization of access site trauma and intimal hyperplasia following use of a 7F sheathless guide versus 6F sheath/guide combination for transradial artery PCI: Results of the PRAGMATIC trial. Am Heart J. 2018 Apr;198:75-83. doi: 10.1016/j.ahj.2017.11.017. Epub 2017 Dec 15.'}, {'pmid': '22784638', 'type': 'BACKGROUND', 'citation': 'Sarkola T, Slorach C, Hui W, Bradley TJ, Redington AN, Jaeggi E. Transcutaneous very-high resolution ultrasound for the quantification of carotid arterial intima-media thickness in children - feasibility and comparison with conventional high resolution vascular ultrasound imaging. Atherosclerosis. 2012 Sep;224(1):102-7. doi: 10.1016/j.atherosclerosis.2012.06.054. Epub 2012 Jun 27.'}, {'pmid': '25100749', 'type': 'BACKGROUND', 'citation': 'Stegemann E, Sansone R, Stegemann B, Kelm M, Heiss C. Validation of High-Resolution Ultrasound Measurements of Intima-Media Thickness of the Radial Artery for the Assessment of Structural Remodeling. Angiology. 2015 Jul;66(6):574-7. doi: 10.1177/0003319714544699. Epub 2014 Aug 5.'}, {'pmid': '26839392', 'type': 'BACKGROUND', 'citation': 'Costa F, van Leeuwen MA, Daemen J, Diletti R, Kauer F, van Geuns RJ, Ligthart J, Witberg K, Zijlstra F, Valgimigli M, Van Mieghem NM. The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures. Circ Cardiovasc Interv. 2016 Feb;9(2):e003129. doi: 10.1161/CIRCINTERVENTIONS.115.003129.'}, {'pmid': '19647922', 'type': 'BACKGROUND', 'citation': 'Foster FS, Mehi J, Lukacs M, Hirson D, White C, Chaggares C, Needles A. A new 15-50 MHz array-based micro-ultrasound scanner for preclinical imaging. Ultrasound Med Biol. 2009 Oct;35(10):1700-8. doi: 10.1016/j.ultrasmedbio.2009.04.012. Epub 2009 Aug 3.'}, {'pmid': '15620487', 'type': 'BACKGROUND', 'citation': 'Jester A, Harth A, Wind G, Germann G, Sauerbier M. Disabilities of the arm, shoulder and hand (DASH) questionnaire: Determining functional activity profiles in patients with upper extremity disorders. J Hand Surg Br. 2005 Feb;30(1):23-8. doi: 10.1016/j.jhsb.2004.08.008.'}, {'pmid': '23420446', 'type': 'BACKGROUND', 'citation': 'Shroff A, Siddiqui S, Burg A, Singla I. Identification and management of complications of transradial procedures. Curr Cardiol Rep. 2013 Apr;15(4):350. doi: 10.1007/s11886-013-0350-x.'}, {'pmid': '18726956', 'type': 'BACKGROUND', 'citation': 'Pancholy S, Coppola J, Patel T, Roke-Thomas M. Prevention of radial artery occlusion-patent hemostasis evaluation trial (PROPHET study): a randomized comparison of traditional versus patency documented hemostasis after transradial catheterization. Catheter Cardiovasc Interv. 2008 Sep 1;72(3):335-340. doi: 10.1002/ccd.21639.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Individual patient data including demographics, cardiac history indications for cardiac catheterization and all follow up data related to primary outcome, secondary ultrasound endpoints, interventional endpoints and secondary functional outcomes will be shared.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF']}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M10016', 'name': 'Hyperplasia', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, 'NCT01406236': {'protocolSection': {'identificationModule': {'nctId': 'NCT01406236', 'orgStudyIdInfo': {'id': 'Pro00030109'}, 'organization': {'fullName': 'Duke University', 'class': 'OTHER'}, 'briefTitle': 'SAFE-PCI for Women', 'officialTitle': 'Study of Access Site for Enhancement of PCI for Women (SAFE-PCI for Women)', 'acronym': 'SAFE-PCI'}, 'statusModule': {'statusVerifiedDate': '2015-01', 'overallStatus': 'TERMINATED', 'whyStopped': 'Study stopped for Statistical Futility. Low rate of bleeding events made it unlikely there would be statistical power to show a difference in the 2 arms.', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-08'}, 'primaryCompletionDateStruct': {'date': '2013-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2013-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-06-20', 'studyFirstSubmitQcDate': '2011-07-29', 'studyFirstPostDateStruct': {'date': '2011-08-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-01-16', 'lastUpdatePostDateStruct': {'date': '2015-01-21', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Duke University', 'class': 'OTHER'}, 'collaborators': [{'name': 'American College of Cardiology', 'class': 'OTHER'}, {'name': 'Abbott Medical Devices', 'class': 'INDUSTRY'}, {'name': 'Lilly USA', 'class': 'UNKNOWN'}, {'name': 'Medtronic', 'class': 'INDUSTRY'}, {'name': 'Terumo Medical Corporation', 'class': 'INDUSTRY'}, {'name': 'The Medicines Company', 'class': 'INDUSTRY'}, {'name': 'Acist Medical Systems', 'class': 'INDUSTRY'}, {'name': 'Guerbet', 'class': 'INDUSTRY'}, {'name': 'Food and Drug Administration (FDA)', 'class': 'FED'}]}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The hypothesis of the SAFE-PCI for women trial is that, compared with transfemoral PCI, transradial PCI will result in a significant reduction in bleeding and vascular complications. The primary objective is to compare the efficacy and feasibility of the transradial approach to percutaneous coronary intervention (PCI) in women compared with the transfemoral approach.\n\nThis study is a multicenter, randomized, open-label active controlled study. Three thousand women undergoing urgent or elective PCI from at least 50 centers will be randomized to either transradial or transfemoral PCI. Patients who are enrolled at sites performing ad hoc PCI will be randomized before diagnostic angiography. A total of approximately 3000 women will be randomized to obtain a cohort of approximately 1800 patients undergoing PCI.\n\nThe Data Safety Monitoring Board has alerted us that the bleeding event rate overall in our trial is very low, making it unlikely that there will be statistical power to show a difference between the randomized arms in the SAFE PCI for Women study using the BARC bleeding definition per protocol. Based on this statistical futility, the DSMB has recommended stopping enrollment. They also noted, however, that as this is not based on any safety issues, and since there are a variety of key secondary endpoints (contrast and radiation exposure, quality of life) that are of clinical and scientific interest, the DSMB left it to the discretion of the Steering Committee to continue enrollment to meet sufficient power for these outcomes. On March 1, 2013, the Steering Committee met to discuss these issues and voted to continue enrollment until the planned sample size for the Quality of Life substudy was met (300 patients).'}, 'conditionsModule': {'conditions': ['Percutaneous Coronary Intervention', 'Ischemic Symptoms'], 'keywords': ['Female', 'urgent or elective percutaneous coronary intervention', 'PCI', 'diagnostic angiography']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 1787, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Transradial PCI', 'type': 'OTHER', 'interventionNames': ['Procedure: Transradial PCI']}, {'label': 'Transfemoral PCI', 'type': 'OTHER', 'interventionNames': ['Procedure: Transfemoral PCI']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Transradial PCI', 'description': 'Transradial PCI', 'armGroupLabels': ['Transradial PCI']}, {'type': 'PROCEDURE', 'name': 'Transfemoral PCI', 'description': 'Transfemoral PCI', 'armGroupLabels': ['Transfemoral PCI']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Primary Efficacy Endpoint: Composite of BARC Types 2, 3, and 5 bleeding or vascular complications.', 'timeFrame': 'From first arterial access post-randomization to 72 hours or hospital discharge, whichever occurs first.'}, {'measure': 'Primary Feasibility Endpoint: Procedural failure, defined as inability to complete the procedure from the assigned vascular access site.', 'timeFrame': 'From first arterial access post-randomization to 72 hours or hospital discharge, whichever occurs first.'}], 'secondaryOutcomes': [{'measure': 'Procedure Duration, total radiation dose and total contrast volume', 'description': 'To determine the effect of transradial PCI on procedure time, total radiation dose, and total contrast volume.', 'timeFrame': '72 hours post randomization or hospital discharge (whichever occurs first)'}, {'measure': 'Resource Use, patient preferences and quality of life', 'description': 'To determine the effect of transradial PCI on resource use, patient preferences, and quality of life.', 'timeFrame': 'Baseline, 72 hours post randomization or hospital discharge (whichever occurs first), 30 day'}, {'measure': '30-day death, vascular complications, or repeat revascularization', 'description': 'To determine the effect of transradial PCI on 30-day death, vascular complications, or repeat revascularization.', 'timeFrame': '30 day'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Have the capacity to understand and sign an informed consent form\n* Age ≥ 18 years\n* Female patient undergoing urgent or elective PCI or undergoing diagnostic angiography to evaluate ischemic symptoms with the possibility of PCI\n\nExclusion Criteria:\n\n* Peripheral arterial disease that prohibits vascular access\n* Bilateral abnormal Barbeau tests\n* Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (note that the opposite arm may be used for radial access in case a dialysis graft is present in one arm provided that the opposite arm has a normal Barbeau test)\n* International normalized ratio (INR) ≥ 1.5 in a patient treated with oral vitamin K antagonists (i.e., warfarin).\n* Receipt of oral Factor Xa or IIa inhibitors ≤ 24 hours prior to the procedure\n* Planned staged PCI within 30 days of index procedure\n* Valvular heart disease requiring valve surgery\n* Planned right-heart catheterization\n* Primary PCI for ST-segment elevation myocardial infarction\n* Presence of bilateral internal mammary artery coronary bypass grafts\n* Unable to provide informed consent\n* Participation in any investigational drug or device study currently or within 30 days prior to enrollment', 'healthyVolunteers': False, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Sunil V Rao, MD', 'affiliation': 'Duke University', 'role': 'PRINCIPAL_INVESTIGATOR'}]}, 'referencesModule': {'references': [{'pmid': '31014090', 'type': 'DERIVED', 'citation': 'Rymer JA, Kaltenbach LA, Kochar A, Hess CN, Gilchrist IC, Messenger JC, Harrington RA, Jolly SS, Jacobs AK, Abbott JD, Wojdyla DM, Krucoff MW, Rao SV. Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circ Cardiovasc Interv. 2019 May;12(5):e007086. doi: 10.1161/CIRCINTERVENTIONS.118.007086.'}, {'pmid': '25147030', 'type': 'DERIVED', 'citation': 'Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, Jorgensen JP, Mazzaferri EL Jr, Jolly SS, Jacobs A, Newby LK, Gibson CM, Kong DF, Mehran R, Waksman R, Gilchrist IC, McCourt BJ, Messenger JC, Peterson ED, Harrington RA, Krucoff MW. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014 Aug;7(8):857-67. doi: 10.1016/j.jcin.2014.04.007.'}, {'pmid': '24016489', 'type': 'DERIVED', 'citation': 'Hess CN, Rao SV, Kong DF, Aberle LH, Anstrom KJ, Gibson CM, Gilchrist IC, Jacobs AK, Jolly SS, Mehran R, Messenger JC, Newby LK, Waksman R, Krucoff MW. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). Am Heart J. 2013 Sep;166(3):421-8. doi: 10.1016/j.ahj.2013.06.013. Epub 2013 Jul 23.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-25'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}}
Creating 1-v-1 comparison report for NCT ID: NCT01398254
2025-08-26 21:50:47,182 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

   * **Study Design**: The primary user study is a Retrospective Observational Study, while the comparator clinical trial (NCT01398254) is an Interventional study with a Randomized design. The randomized interventional study design is generally considered more robust as it minimizes bias and allows for a direct comparison between interventions.

   * **Patient Population**: The primary user study involved 7,121 patients who underwent PCI procedures at five U.S. centers. In contrast, the comparator clinical trial involved 2,292 patients undergoing primary percutaneous intervention (PPCI) at multiple locations in Canada. Both studies included patients undergoing PCI procedures, but the primary user study had a larger sample size.

   * **Advancement/Limitation**: The primary user study's methodology appears more robust due to its larger sample size, which can increase the statistical power and the reliability of the results. However, the comparator clinical trial's randomized design is a significant advantage as it can help eliminate bias and confounding factors.

**2. Intervention & Endpoints Comparison:**

   * **Intervention**: Both studies compared the same primary interventions and comparators - transradial percutaneous coronary intervention (TRI) and transfemoral percutaneous coronary intervention (TFI).

   * **Endpoints**: The primary user study's primary outcome was the cost of PCI hospitalization, with secondary outcomes including bleeding, in-hospital mortality, and length of stay. The comparator clinical trial's primary outcome was all-cause mortality measured at 30 days, with secondary outcomes including death, reinfarction, stroke, bleeding, and resource utilization. While both studies measured similar secondary outcomes, the primary outcomes were different, focusing on cost in the user study and mortality in the comparator study.

   * **Advancement/Limitation**: The primary user study's focus on cost as a primary outcome is a novel aspect, providing valuable information on the economic impact of the interventions. The comparator clinical trial, on the other hand, provides a more comprehensive view of clinical outcomes, including mortality, reinfarction, and stroke.

**3. Overall Assessment:**

   * **Conclusion**: The key difference between these two studies lies in their primary focus - the primary user study focuses on the cost-effectiveness of TRI vs. TFI, while the comparator clinical trial focuses on the clinical outcomes of these interventions. Both studies provide valuable insights into different aspects of TRI and TFI, contributing to a comprehensive understanding of these interventions' benefits and drawbacks.
****************************
Creating 1-v-1 comparison report for NCT ID: NCT02831166
2025-08-26 21:51:03,516 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

- **Study Design**: The primary user study is a Retrospective Observational Study, while the comparator clinical trial (NCT02831166) is an Interventional study with a Randomized design. The randomized interventional study design is generally considered more robust as it minimizes bias and allows for a direct comparison between interventions.

- **Patient Population**: The primary user study involved a larger sample size of 7,121 patients who underwent PCI procedures at five U.S. centers, while the comparator clinical trial involved 250 patients undergoing primary percutaneous coronary intervention at a single center in Brazil. The larger sample size and multi-center design of the primary user study may provide a more representative and generalizable patient population.

- **Advancement/Limitation**: The primary user study's methodology appears more robust due to its larger sample size and multi-center design. However, the comparator clinical trial's randomized design is a significant advantage as it allows for a more controlled comparison between interventions.

**2. Intervention & Endpoints Comparison:**

- **Intervention**: Both studies compared the transradial (TRI) and transfemoral (TFI) approaches to percutaneous coronary intervention (PCI). However, the comparator clinical trial also included the use of a vascular closure device in the TFI group.

- **Endpoints**: The primary user study focused on the cost of PCI hospitalization as the primary outcome, with secondary outcomes including bleeding, in-hospital mortality, and length of stay. The comparator clinical trial, on the other hand, focused on major vascular access site complications as the primary outcome, with device success as a secondary outcome. The endpoints are somewhat similar, with both studies considering complications related to the procedures.

- **Advancement/Limitation**: The primary user study's focus on cost as a primary outcome is a unique aspect that provides valuable information for healthcare decision-making. The comparator clinical trial's inclusion of a vascular closure device in the TFI group is a novel intervention that could potentially improve outcomes in this group.

**3. Overall Assessment:**

- **Conclusion**: Both studies compare the TRI and TFI approaches to PCI, with a focus on complications related to the procedures. The primary user study provides valuable information on the cost-effectiveness of the TRI approach, while the comparator clinical trial introduces a novel intervention in the TFI group. The key difference between the two studies lies in their primary outcomes and the inclusion of a vascular closure device in the comparator clinical trial.
****************************
Creating 1-v-1 comparison report for NCT ID: NCT01803841
2025-08-26 21:51:21,283 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

- **Study Design**: The primary user study is a retrospective observational study, while the comparator clinical trial (NCT01803841) is an interventional study. The observational study design involves observing subjects and measuring variables of interest without assigning treatments or interventions. In contrast, the interventional study actively manipulates the study subjects' exposure to the intervention and compares the outcomes.

- **Patient Population**: The primary user study involved 7,121 patients who underwent PCI procedures at five U.S. centers. Of these, 1,219 (17%) patients underwent TRI. The comparator clinical trial involved a larger sample size of 7,300 patients undergoing coronary angiography or percutaneous coronary intervention either transradial or transfemoral approach from 22 centers in South Korea.

- **Advancement/Limitation**: The comparator clinical trial's methodology appears more robust due to its larger sample size and interventional study design, which allows for a more direct comparison of outcomes between the two intervention groups. However, the primary user study's retrospective design may limit its ability to establish causality between the intervention and outcomes.

**2. Intervention & Endpoints Comparison:**

- **Intervention**: Both studies compared the same primary interventions and comparators, namely transradial percutaneous coronary intervention (TRI) and transfemoral percutaneous coronary intervention (TFI).

- **Endpoints**: The primary user study's primary outcome was the cost of PCI hospitalization, while secondary outcomes included bleeding, in-hospital mortality, and length of stay. The comparator clinical trial's primary outcome was a patient-oriented composite outcome, including any death, non-fatal myocardial infarction, and any revascularization. Secondary outcomes included access failure, success of percutaneous coronary intervention, procedure time, and fluoroscopic time. The endpoints are not similar, with the primary user study focusing more on cost and hospitalization aspects, while the comparator clinical trial focuses more on clinical outcomes and procedural aspects.

- **Advancement/Limitation**: The primary user study's focus on cost savings represents a novel aspect not covered in the comparator clinical trial. However, the comparator clinical trial includes more comprehensive clinical endpoints, including a composite of death, myocardial infarction, and revascularization.

**3. Overall Assessment:**

- **Conclusion**: The key difference between these two studies lies in their focus and endpoints. The primary user study focuses on the cost savings and hospitalization aspects of TRI versus TFI, finding that TRI was associated with a total cost savings of $830 per patient. In contrast, the comparator clinical trial focuses more on clinical outcomes and procedural aspects of TRI versus TFI, with no mention of cost savings. Both studies contribute valuable insights into different aspects of TRI versus TFI, highlighting the need for a comprehensive approach when evaluating these interventions.
****************************
Creating 1-v-1 comparison report for NCT ID: NCT01794325
2025-08-26 21:51:39,097 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

- **Study Design**: The primary user study is a Retrospective Observational Study, while the comparator clinical trial (NCT01794325) is an Interventional study with a Randomized, Non-inferiority Trial design. The primary user study retrospectively analyzed existing data, while the comparator study actively intervened and randomized patients to different treatment groups.

- **Patient Population**: The primary user study involved a larger sample size of 7,121 patients who underwent PCI procedures at five U.S. centers. The comparator study, on the other hand, estimated a smaller sample size of 300 patients undergoing coronary angiography, with no specific location mentioned.

- **Advancement/Limitation**: The primary user study's methodology appears more robust due to its larger sample size and multi-center design, which may increase the generalizability of the findings. However, the comparator study's randomized design can better control for confounding variables and establish causality.

**2. Intervention & Endpoints Comparison:**

- **Intervention**: Both studies compared the transradial (TRI) and transfemoral (TFI) approaches in coronary procedures. However, the primary user study focused on percutaneous coronary intervention (PCI), while the comparator study focused on coronary angiography.

- **Endpoints**: The primary user study's primary outcome was the cost of PCI hospitalization, with secondary outcomes including bleeding, in-hospital mortality, and length of stay. The comparator study's primary outcome was patient radiation exposure during coronary angiography, with secondary outcomes including physician radiation exposure and major adverse cardiac events.

- **Advancement/Limitation**: The primary user study's focus on cost and outcomes provides valuable information for healthcare decision-making. The comparator study's focus on radiation exposure provides important safety information but does not directly address cost or clinical outcomes.

**3. Overall Assessment:**

- **Conclusion**: The primary user study and the comparator study both compared TRI and TFI in coronary procedures, but they had different focuses and methodologies. The primary user study focused on cost and clinical outcomes in a large, multi-center retrospective observational study, finding that TRI was associated with cost savings and better outcomes. The comparator study focused on radiation exposure in a smaller, randomized trial, with no results currently available. The two studies complement each other by providing different perspectives on the TRI vs. TFI comparison.
****************************
Creating 1-v-1 comparison report for NCT ID: NCT01364532
2025-08-26 21:51:53,545 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

- **Study Design**: The primary user study is a Retrospective Observational Study, while the comparator clinical trial (NCT01364532) is an Interventional Randomized Controlled Trial (RCT). The RCT design is generally considered more robust as it minimizes bias and allows for a direct comparison between interventions.

- **Patient Population**: The primary user study involved a larger sample size of 7,121 patients who underwent PCI procedures at five U.S. centers. The comparator clinical trial had an estimated enrollment of 572 patients. The primary user study did not provide detailed patient characteristics, while the comparator clinical trial included patients aged 19 years and above, excluding those with cardiogenic shock, hemodynamic instability, chronic hemodialysis, or previous coronary artery bypass grafting.

- **Advancement/Limitation**: The comparator clinical trial's methodology appears more robust due to its RCT design. However, the primary user study's larger sample size and multi-center design could provide a more representative and generalizable result.

**2. Intervention & Endpoints Comparison:**

- **Intervention**: Both studies compared the transradial approach for PCI. However, the primary user study compared it to the transfemoral approach, while the comparator clinical trial compared it to the transulnar approach.

- **Endpoints**: The primary user study's primary outcome was the cost of PCI hospitalization, with secondary outcomes including bleeding, in-hospital mortality, and length of stay. The comparator clinical trial's primary outcome was successful arterial access free from need for crossover and free from vascular or coronary ischemic complications within 60± days. Its secondary outcomes included fluoroscopy time, amount of contrast medium, vascular complications, and procedural duration.

- **Advancement/Limitation**: The primary user study's focus on cost outcomes is a unique aspect not covered in the comparator clinical trial. However, the comparator clinical trial includes more comprehensive endpoints, including specific procedural characteristics and complications. 

**3. Overall Assessment:**

- **Conclusion**: The key difference between these two studies lies in their comparators and outcomes of interest. The primary user study compared the transradial approach to the transfemoral approach and focused on cost outcomes. In contrast, the comparator clinical trial compared the transradial approach to the transulnar approach and focused on procedural success and complications. Both studies contribute valuable insights into different aspects of PCI procedures.
****************************
Creating 1-v-1 comparison report for NCT ID: NCT04801901
2025-08-26 21:52:09,933 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

- **Study Design**: The primary user study is a Retrospective Observational Study, while the comparator clinical trial (NCT04801901) is an Interventional study with a randomized design. The primary user study retrospectively analyzed existing data, while the comparator study prospectively assigned participants to receive specific interventions.

- **Patient Population**: The primary user study involved a larger sample size of 7,121 patients who underwent PCI procedures at five U.S. centers. The comparator study, on the other hand, had a smaller sample size of 64 patients undergoing cardiac catheterization at the INOVA Heart and Vascular Institute.

- **Advancement/Limitation**: The primary user study's methodology appears more robust due to its larger sample size, which can provide more reliable and generalizable results. However, the comparator study's randomized design can better control for confounding factors and establish causality.

**2. Intervention & Endpoints Comparison:**

- **Intervention**: Both studies focused on different types of transradial access for coronary procedures. The primary user study compared transradial percutaneous coronary intervention (TRI) with transfemoral percutaneous coronary intervention (TFI). The comparator study compared distal transradial access (dTRA) with standard forearm transradial access (fTRA).

- **Endpoints**: The primary user study's primary outcome was the cost of PCI hospitalization, with secondary outcomes including bleeding, in-hospital mortality, and length of stay. The comparator study's primary outcome was the radial artery intimal medial thickness following dTRA and fTRA, with secondary outcomes including metrics of procedural success and functional assessment of pain and motor strength of the ipsilateral upper extremity.

- **Advancement/Limitation**: The primary user study's focus on cost savings and clinical outcomes like bleeding and mortality provides valuable information for healthcare decision-making. The comparator study, however, provides more detailed insights into the physiological impacts of different transradial access methods.

**3. Overall Assessment:**

- **Conclusion**: The key difference between these two studies lies in their focus and methodology. The primary user study focused on the cost-effectiveness and clinical outcomes of TRI versus TFI, providing valuable insights for healthcare decision-making. The comparator study, on the other hand, focused on the physiological impacts of different transradial access methods, contributing to the understanding of these procedures' safety and efficacy. Both studies contribute valuable knowledge to the field of transradial access for coronary procedures.
****************************
Creating 1-v-1 comparison report for NCT ID: NCT01406236
2025-08-26 21:52:27,229 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**1. Methodology Comparison:**

- **Study Design**: The primary user study is a Retrospective Observational Study, while the comparator clinical trial (NCT01406236) is an Interventional study with a randomized, open-label active controlled design. The interventional study design is generally considered more robust as it allows for random assignment of participants to different groups, reducing the risk of bias.

- **Patient Population**: The primary user study involved 7,121 patients who underwent PCI procedures at five U.S. centers. In contrast, the comparator clinical trial involved 1,787 women undergoing urgent or elective PCI from at least 50 centers. The primary user study had a larger sample size, which can increase the statistical power of the study. However, the comparator clinical trial had a more specific patient population (women), which can provide more targeted insights.

- **Advancement/Limitation**: The primary user study's methodology appears more robust in terms of sample size. However, the comparator clinical trial's methodology is more advanced in terms of study design (randomized controlled trial) and patient population specificity.

**2. Intervention & Endpoints Comparison:**

- **Intervention**: Both studies compared the same primary interventions and comparators, i.e., transradial percutaneous coronary intervention (TRI) and transfemoral percutaneous coronary intervention (TFI).

- **Endpoints**: The primary user study's primary outcome was the cost of PCI hospitalization, while secondary outcomes included bleeding, in-hospital mortality, and length of stay. The comparator clinical trial's primary outcomes were a composite of BARC Types 2, 3, and 5 bleeding or vascular complications and procedural failure. Secondary outcomes included procedure duration, total radiation dose, total contrast volume, resource use, patient preferences, quality of life, and 30-day death, vascular complications, or repeat revascularization. The comparator clinical trial had more comprehensive endpoints.

- **Advancement/Limitation**: The comparator clinical trial had more comprehensive endpoints, including quality of life and patient preferences, which are important aspects of patient-centered care.

**3. Overall Assessment:**

- **Conclusion**: Both studies focused on comparing the outcomes of TRI and TFI. The primary user study found that TRI was associated with cost savings, shorter lengths of stay, and lower bleeding events. The comparator clinical trial aimed to compare the efficacy and feasibility of the transradial approach to PCI in women with the transfemoral approach. However, the comparator clinical trial was terminated due to statistical futility, as the low rate of bleeding events made it unlikely to show a difference in the two arms. The key difference between the two studies lies in their focus: the primary user study focused on cost-effectiveness, while the comparator clinical trial focused on efficacy and feasibility.
****************************
2025-08-26 21:52:52,947 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
**Executive Summary**

1. **Overall Market Position**: The primary study's methodology and findings are generally in line with the landscape of the competitor trials. The primary study's focus on cost-effectiveness of transradial percutaneous coronary intervention (TRI) versus transfemoral percutaneous coronary intervention (TFI) is a unique aspect that sets it apart from most competitor trials, which primarily focus on clinical outcomes. The primary study's large sample size and multi-center design also provide a robust and representative dataset.

2. **Key Differentiators & Gaps**: The primary study's most significant scientific advantage is its focus on cost-effectiveness, which provides valuable insights for healthcare decision-making. However, the primary study lacks some of the comprehensive clinical endpoints found in competitor trials, such as specific procedural characteristics, radiation exposure, and quality of life measures. Additionally, the primary study's retrospective observational design may limit its ability to establish causality compared to the randomized controlled trials used in competitor studies.

3. **Consensus and Outliers**: The primary study's findings are consistent with the general conclusions from the competitor trials in terms of the benefits of TRI over TFI. However, the primary study presents a novel result in terms of cost savings, finding that TRI was associated with a total cost savings of $830 per patient compared to TFI.

4. **Strategic Recommendation**: Based on this benchmark, the single most important strategic action to consider is to publish the primary study's findings to highlight the cost-effectiveness advantage of TRI over TFI. This could help to position TRI as a more cost-effective option for percutaneous coronary intervention, potentially influencing clinical practice and healthcare policy.

5. **Methodology Comparison**:
   * **Study Design**: The primary study is a retrospective observational study, while most competitor trials are randomized controlled trials.
   * **Patient Population**: The primary study has a larger sample size and a multi-center design, which may provide more representative and generalizable results. However, some competitor trials have more specific patient populations, such as women or patients undergoing specific procedures.
   * **Advancement/Limitation**: The primary study's methodology appears more robust in terms of sample size and multi-center design. However, the randomized controlled design used in competitor trials can better control for confounding factors and establish causality.

6. **Intervention & Endpoints Comparison**:
   * **Intervention**: Both the primary study and competitor trials compare TRI and TFI.
   * **Endpoints**: The primary study focuses on cost as the primary outcome, with secondary outcomes including bleeding, in-hospital mortality, and length of stay. Competitor trials often focus on clinical outcomes, with some also including procedural characteristics and quality of life measures.
   * **Advancement/Limitation**: The primary study's focus on cost outcomes is a unique aspect not covered in most competitor trials. However, competitor trials often include more comprehensive clinical endpoints.

7. **Overall Assessment**:
   * **Conclusion**: The primary study and competitor trials all compare TRI and TFI, but they have different focuses and methodologies. The primary study focuses on cost-effectiveness and finds that TRI is associated with cost savings and better outcomes. Competitor trials often focus on clinical outcomes and use randomized controlled designs. Both the primary study and competitor trials contribute valuable knowledge to the field of percutaneous coronary intervention.